Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096949 · ClinicalTrials.gov registry record · NA
Implementing Cabenuva in Arkansas HIV Programs
A NA study, sponsored by University of Arkansas.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT05096949 is a NA study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 1 participants.
The verdict
NCT05096949, a NA study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study seeks to address this gap by studying two Cabenuva delivery strategies conducted at six outpatient HIV clinics in Arkansas, a Southern state with a large population of rural, poor, and African-American residents. The two delivery strategies are clinic delivery and home delivery. In the clinic delivery study arm patients will receive Cabenuva injections at the clinic (50 patients), and in the home delivery study arm patients will receive the injections at home (50 patients). The study team will follow the patients in both study arms for 10 months. After 5 months, the patients will complete a treatment satisfaction survey, and after 10 months the study team will examine clinic records to assess their medication adherence. Secondary outcomes will include clinician perceptions of acceptability, feasibility, and appropriateness of Cabenuva delivery strategies. The study team will also collect qualitative data from patients and clinic employees to learn more in depth about their perceptions of Cabenuva, the delivery strategies, their implementation, and barriers and facilitators. Finally, the study team will estimate the costs associated with the two delivery strategies from the clinic and patient perspectives. The data from this study provide information on what delivery strategies for long acting HIV medications offer best results, how these strategies are perceived by patients and clinicians, and how costly and feasible the strategies are to implement in practice.
Interventions
- OTHER Home visit delivery strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096949
The ClinicalTrials.gov registry entry for NCT05096949 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Home visit delivery strategy is the first listed.
NCT05096949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096949 about?
NCT05096949 is a clinical study titled "Implementing Cabenuva in Arkansas HIV Programs". This study seeks to address this gap by studying two Cabenuva delivery strategies conducted at six outpatient HIV clinics in Arkansas, a Southern state with a large population of rural, poor, and African-American residents. The two delivery strategies are clinic delivery and home delivery. In the cl...
What is the current status of trial NCT05096949?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2022-03-07. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05096949?
The interventions under investigation include: Home visit delivery strategy (OTHER).
Who is sponsoring clinical trial NCT05096949?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.